IMEDA

IMEDA (International Medical Device Manufacturers Association) is the non-profit organization integrating the international producers of the medical equipment, products and supplies presented at the Russian market. As of 2017, the association integrates more than 40 international companies working in the field of hi-tech medicine.

Priority tasks of association are development of favorable legal and economic climate in the field of health care, increase in ethical standards of the industry and formation of the consolidated position of producers of medical products on development and regulation of the industry. IMEDA actively cooperates with the international and foreign associations of producers of medical products, monitoring all significant global trends and collecting the best world practices of regulation of the industry.

History

2017

Election of the chairman and board members

The CEO of Johnson & Johnson in Russia and the CIS countries Yulia Markova became the chairman of the board of directors of Association of the international producers of the medical products IMEDA. The next elections to managing body of association took place on November 20, 2017 at the General meeting of heads of the companies entering into IMEDA.

The head of the Russian office Johnson & Johnson Yulia Markova headed Board of Directors of IMEDA

In addition to Markova, for the next two years were elected as a member of Board of Directors of IMEDA: Svetlana Gerbel (Siemens Healthineers), Maxim Kuznetsov (Philips), Elena Plyasunova (Medtronic) and Elena Syabrenko (Olympus).

The Board of Directors of IMEDA defines tactics of execution of tasks of association, sets control of the budget, employs the staff of Administration of association (including the chief executive). The questions entering a zone of interests of association are submitted by Board of Directors for consideration and the analysis within standing committees or special temporary work groups of association.^[1]

The request to the Government to review criteria of pricing for medical implants

The association of the international producers of the medical products IMEDA in November, 2017 directed addressed to the Deputy Prime Minister of the Russian Federation Olga Golodets the letter with a request to review provisions of Order of the Government of the Russian Federation No. 1517 of December 30, 2015 "About state regulation of the prices of the medical products included in the list of the medical products implanted into a human body at delivery of health care within the program of the state guarantees of free rendering medical care to citizens".^[2]

On belief of representatives of IMEDA, the existing mechanism of state price regulation can become the reason of decrease in availability of medical implants as a result. Photo: inteknopend.blogspot.ru

On belief of representatives of IMEDA, the technique described in the order of the Government of the Russian Federation allows to understand too widely the term "marginal selling price of the producer" for the groups different in the characteristics and a purpose of goods, and the lack of accurate determinations of key concepts of a result allows various, occasionally free interpretations of terms at the regional level.

As you know, in September, 2017 regional wholesale allowances which in a number of areas made 1% for the most expensive technologies were set. Such state of affairs, consider in IMEDA, can lead as a result to decrease in availability of "the innovation implanted medical products" to the public medical institutions and as result, to threaten a possibility of receiving hi-tech medical care by citizens as the price of them is higher, than on normal products.

Since 2018 will earn the Uniform directory of goods, works and services which will include also implanted medical products. With respect thereto representatives of IMEDA in the letter ask to review criteria of pricing or to repeal the resolution as further use of this mechanism on the separate taken group of medical products is "excessive and inexpedient".

The law on state price regulation on the implanted medical products was adopted at the beginning of 2015 for the purpose of price stabilization and restriction of speculation. It was originally supposed that it will become effective in 2016, however then introduction of state regulation was postponed to the end of 2017.

Change of the chief executive

At the end of July, 2017 in IMEDA association there was a change of the executive management — instead of Sergey Kolosov the association was headed by the chief executive Sergey Vanin.

Notes